• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清护骨素检测在慢性肾脏病-矿物质和骨异常早期诊断中的应用。

Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder.

机构信息

Department of Nephrology, General Hospital of Tianjin Medical University, Tianjin, China.

出版信息

Nephrology (Carlton). 2011 Aug;16(6):588-94. doi: 10.1111/j.1440-1797.2011.01481.x.

DOI:10.1111/j.1440-1797.2011.01481.x
PMID:21649792
Abstract

AIM

Chronic kidney disease-mineral and bone disorder (CKD-MBD) has been proposed to be the replacement of renal osteodystrophy by the Organization of Kidney Disease: Improving Global Outcomes since 2005 because the mineral disorder is not confined to the skeleton in CKD. Accordingly, laboratory and imaging tests have been emphasized for the clinical assessment of patients with CKD besides renal biopsy. The objective of the current study was to investigate whether osteoprotegerin (OPG) could be made a useful biomarker for early diagnosis of CKD-MBD.

METHODS

Sixty pre-dialysis patients with CKD 1-5 were enrolled in this study. The serum calcium, phosphorus, blood urea nitrogen, creatinine, alkaline phosphatase, Osteocalcin, Calcitonin, intact parathyroid hormone and OPG were measured. Bone mineral densities of the lumbar spine (L2-L4), femoral neck, Ward's triangle and trochanter were measured by dual-energy X-ray absorptiometry.

RESULTS

Among all measured serum bone metabolism indexes, the changing of serum OPG level happened at the earliest time (CKD 3) and its correlation coefficient with estimated glomerular filtration rate (eGFR) was also the highest (r = -0.601, P = 0.001). In the multivariable analysis that included sex, age and eGFR as controlling factors, the serum OPG correlated with the bone mineral density (BMD) of Ward's triangle (r = -0.390, P = 0.041).

CONCLUSION

Serum OPG may be a useful biomarker for early diagnosis of CKD-MBD.

摘要

目的

自 2005 年以来,肾脏病:改善全球预后组织(Kidney Disease: Improving Global Outcomes,KDIGO)提出用慢性肾脏病-矿物质和骨异常(Chronic kidney disease-mineral and bone disorder,CKD-MBD)取代肾性骨营养不良,因为矿物质异常并不仅局限于 CKD 患者的骨骼。因此,除了肾活检外,实验室和影像学检查也被强调用于 CKD 患者的临床评估。本研究旨在探讨骨保护素(Osteoprotegerin,OPG)是否可作为 CKD-MBD 早期诊断的有用生物标志物。

方法

本研究纳入了 60 名 1-5 期的未透析 CKD 患者。检测了血清钙、磷、尿素氮、肌酐、碱性磷酸酶、骨钙素、降钙素、全段甲状旁腺激素和 OPG。采用双能 X 线吸收法检测了腰椎(L2-L4)、股骨颈、Ward 三角和转子间的骨矿物质密度。

结果

在所有检测的血清骨代谢指标中,血清 OPG 水平的变化最早出现(CKD 3 期),其与估算肾小球滤过率(estimated glomerular filtration rate,eGFR)的相关系数也最高(r = -0.601,P = 0.001)。在包含性别、年龄和 eGFR 作为控制因素的多变量分析中,血清 OPG 与 Ward 三角的骨矿物质密度(bone mineral density,BMD)相关(r = -0.390,P = 0.041)。

结论

血清 OPG 可能是 CKD-MBD 早期诊断的有用生物标志物。

相似文献

1
Serum osteoprotegerin measurement for early diagnosis of chronic kidney disease-mineral and bone disorder.血清护骨素检测在慢性肾脏病-矿物质和骨异常早期诊断中的应用。
Nephrology (Carlton). 2011 Aug;16(6):588-94. doi: 10.1111/j.1440-1797.2011.01481.x.
2
Relation between body mass index and bone mineral density among haemodialysis patients with chronic kidney disease.慢性肾病血液透析患者体重指数与骨矿物质密度的关系
J Ren Care. 2009 Mar;35 Suppl 1:57-64. doi: 10.1111/j.1755-6686.2009.00039.x.
3
Associations between osteoprotegerin and femoral neck BMD in hemodialysis patients.血液透析患者中骨保护素与股骨颈骨密度的关联。
J Bone Miner Metab. 2008;26(1):66-72. doi: 10.1007/s00774-007-0785-5. Epub 2008 Jan 10.
4
OSTEOPROTEGERIN AS AN EARLY SIGN OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER.骨钙素作为慢性肾脏病-矿物质和骨异常的早期标志物。
Acta Clin Croat. 2023 Jul;62(Suppl2):46-52. doi: 10.20471/acc.2023.62.s2.7.
5
Osteoprotegerin and bone mineral density in hemodiafiltration patients.血液透析滤过患者的骨保护素与骨密度
Ren Fail. 2005;27(5):531-9. doi: 10.1080/08860220500198698.
6
Bone mineral densitometry in patients on hemodialysis: difference between genders and what to measure.血液透析患者的骨矿物质密度测定:性别差异及测量内容。
Ren Fail. 2010 Jan;32(3):300-8. doi: 10.3109/08860221003611661.
7
Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.肝素钠对慢性肾脏病大鼠肾性骨营养不良和血管钙化的影响。
Bone. 2014 Jan;58:168-76. doi: 10.1016/j.bone.2013.10.010. Epub 2013 Oct 18.
8
[Double photon absorptiometry in renal osteodystrophy].
Wien Klin Wochenschr. 1990 Mar 2;102(5):136-40.
9
The complexity of chronic kidney disease-mineral and bone disorder across stages of chronic kidney disease.慢性肾脏病-矿物质和骨异常在慢性肾脏病各阶段的复杂性。
Kidney Int. 2017 Jun;91(6):1436-1446. doi: 10.1016/j.kint.2016.12.029. Epub 2017 Mar 18.
10
Bone mineral density and biochemical markers of bone metabolism in predialysis patients with chronic kidney disease.慢性肾脏病透析前患者的骨矿物质密度和骨代谢生化标志物
J Investig Med. 2016 Apr;64(4):861-6. doi: 10.1136/jim-2015-000043. Epub 2016 Mar 11.

引用本文的文献

1
Anemia and Mineral Bone Disorder in Kidney Disease Patients: The Role of FGF-23 and Other Related Factors.肾病患者的贫血与矿物质骨代谢紊乱:成纤维细胞生长因子-23及其他相关因素的作用
Int J Mol Sci. 2024 Nov 29;25(23):12838. doi: 10.3390/ijms252312838.
2
OSTEOPROTEGERIN AS AN EARLY SIGN OF CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER.骨钙素作为慢性肾脏病-矿物质和骨异常的早期标志物。
Acta Clin Croat. 2023 Jul;62(Suppl2):46-52. doi: 10.20471/acc.2023.62.s2.7.
3
Osteoprotegerin and Inflammation in Incident Peritoneal Dialysis Patients.
新发病的腹膜透析患者中的骨保护素与炎症
J Clin Med. 2024 Apr 18;13(8):2345. doi: 10.3390/jcm13082345.
4
Osteoprotegerin is an Early Marker of the Fibrotic Process and of Antifibrotic Treatment Responses in Ex Vivo Lung Fibrosis.骨保护素是肺纤维化体外模型中纤维化过程和抗纤维化治疗反应的早期标志物。
Lung. 2024 Jun;202(3):331-342. doi: 10.1007/s00408-024-00691-5. Epub 2024 Apr 20.
5
An Investigation Into the Role of Osteocalcin in Human Arterial Smooth Muscle Cell Calcification.骨钙素在人动脉平滑肌细胞钙化中的作用研究。
Front Endocrinol (Lausanne). 2020 Jun 10;11:369. doi: 10.3389/fendo.2020.00369. eCollection 2020.
6
Determination of NF-κB and RANKL levels in peripheral blood osteoclast precursor cells in chronic kidney disease patients.慢性肾病患者外周血破骨细胞前体细胞中NF-κB和RANKL水平的测定
Int Urol Nephrol. 2018 Jun;50(6):1181-1188. doi: 10.1007/s11255-018-1859-0. Epub 2018 Apr 11.
7
Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study.血清骨保护素水平与慢性肾脏病骨丢失的关联:来自慢性肾脏病知晓研究的见解
PLoS One. 2016 Nov 17;11(11):e0166792. doi: 10.1371/journal.pone.0166792. eCollection 2016.
8
Serum Osteoprotegerin Levels Related With Cardiovascular Risk Factors in Chronic Kidney Disease.慢性肾脏病中血清骨保护素水平与心血管危险因素的关系
J Clin Lab Anal. 2016 Nov;30(6):811-817. doi: 10.1002/jcla.21941. Epub 2016 Mar 17.
9
Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.慢性肾病患者动脉粥样硬化风险增加的标志物:一项初步研究。
Lipids Health Dis. 2016 Feb 3;15:22. doi: 10.1186/s12944-016-0191-x.
10
Osteoprotegerin and kidney disease.骨保护素与肾脏疾病。
J Nephrol. 2014 Dec;27(6):607-17. doi: 10.1007/s40620-014-0092-x. Epub 2014 Apr 23.